Leteurtre F, Kohlhagen G, Fesen M R, Tanizawa A, Kohn K W, Pommier Y
Laboratory of Molecular Pharmacology, National Cancer Institute, Bethesda, Maryland 20892.
J Biol Chem. 1994 Mar 18;269(11):7893-900.
DNA methylation is deregulated during oncogenesis. Since several major anti-cancer drugs act on topoisomerases, we investigated the effects of cytosine methylation on topoisomerase cleavage activities. Both topoisomerase I and II cleavage patterns were modified by CpG methylation in c-myc gene DNA fragments. Topoisomerase II changes, mainly cleavage reduction, occurred for methylation sites within 7 base pairs from the topoisomerase II breaks and were different for VM-26 and azatoxin. For topoisomerase I, cleavage enhancement as well as suppression were observed. Using synthetic methylated oligonucleotides, we show that hemimethylation is sufficient to alter topoisomerase I activity. Cytosine methylation on the scissile strand within the topoisomerase I consensus sequence had strong effects. Cleavage was stimulated by methylation at position -4 and was strongly inhibited by methylation at position -3 (with position -1 being the enzyme-linked nucleotide). This inhibitory effect was attributed to the presence of a methyl group in the major groove, since the transition uracil to thymine also inhibited cleavage. Altogether these results suggest an interaction of topoisomerase I with the DNA major grove at positions -3 and -4. In addition, DNA methylation may have profound effects on the activity of topoisomerases and may alter the distribution of cleavage sites produced by anticancer drugs in chromatin.
DNA甲基化在肿瘤发生过程中失调。由于几种主要的抗癌药物作用于拓扑异构酶,我们研究了胞嘧啶甲基化对拓扑异构酶切割活性的影响。在c-myc基因DNA片段中,拓扑异构酶I和II的切割模式均因CpG甲基化而改变。拓扑异构酶II的变化主要是切割减少,发生在距拓扑异构酶II断裂点7个碱基对内的甲基化位点,且VM-26和氮杂毒素的情况不同。对于拓扑异构酶I,观察到切割增强以及抑制现象。使用合成的甲基化寡核苷酸,我们表明半甲基化足以改变拓扑异构酶I的活性。拓扑异构酶I共有序列内可裂解链上的胞嘧啶甲基化具有强烈影响。在-4位甲基化刺激切割,而在-3位甲基化则强烈抑制切割(-1位是与酶相连的核苷酸)。这种抑制作用归因于大沟中甲基基团的存在,因为尿嘧啶向胸腺嘧啶的转变也抑制切割。总之,这些结果表明拓扑异构酶I在-3和-4位与DNA大沟相互作用。此外,DNA甲基化可能对拓扑异构酶的活性产生深远影响,并可能改变抗癌药物在染色质中产生的切割位点分布。